Topics

Pharmacokinetic/Pharmacodynamic Modeling of Seven Antimicrobials for Empiric Treatment of Adult Bloodstream Infections with Gram-Negative Bacteria in China.

07:00 EST 2nd December 2019 | BioPortfolio

Summary of "Pharmacokinetic/Pharmacodynamic Modeling of Seven Antimicrobials for Empiric Treatment of Adult Bloodstream Infections with Gram-Negative Bacteria in China."

Optimal dosing regimens for achieving a positive clinical outcome were simulated for seven antibiotics commonly used to treat bloodstream infections (BSIs) in adults. Pharmacokinetic/pharmacodynamic (PK/PD) modeling was used to simulate 17 regimens, including meropenem, imipenem, cefepime, ceftazidime, piperacillin-tazobactam, tigecycline, and polymyxin B based on patients' characteristics and the antimicrobial resistance data for the main pathogens isolated from blood specimens in Shandong province (China). A regimen for which the cumulative fraction of response (CFR) was 90% or more was considered optimal. For and , all carbapenem regimens, ceftazidime (2gq8h, 0.5 hr, and 3hr infusion), and piperacillin/tazobactam (4.5gq8h, 3 hr infusion) achieved CFRs above 90%. The meropenem regimen (2gq8h, 3 hr) achieved CFRs above 90% for both ceftriaxone or cefotaxime-resistant (CRO/CTX-R) and . For , ceftazidime and meropenem (2gq8h, 0.5 hr, and 3 hr infusion) achieved optimal CFRs. None of the β-lactam regimens examined achieved a CFR above 80% for . For all examined bacteria, polymyxin B (50 mg q12h) led to a CFR above 90%. PK/PD modeling based on local antimicrobial resistance data provides valuable guidance for clinicians for the administration of empirical antibiotic treatments for BSIs.

Affiliation

Journal Details

This article was published in the following journal.

Name: Microbial drug resistance (Larchmont, N.Y.)
ISSN: 1931-8448
Pages:

Links

DeepDyve research library

PubMed Articles [23381 Associated PubMed Articles listed on BioPortfolio]

Antimicrobial dosing in Critical Care: A pragmatic adult dosing nomogram.

Standard dosing of antimicrobials derived from product information (PI) is considered to have limited application in critically ill patients given the pharmacokinetic (PK) and pharmacodynamic (PD) cha...

Treatment of the obsessive-compulsive and bipolar disorders comorbidity: Pharmacodynamic and pharmacokinetic evaluation.

: The comorbidity between obsessive-compulsive disorder (OCD) and bipolar disorders (BDs) is a frequent and severe condition characterized by a chronic course, high suicidal risk and tendency towards ...

Pharmacokinetic/ Pharmacodynamic Modeling To Support The Re-Approval Of Gemtuzumab Ozogamicin.

Gemtuzumab ozogamicin (Mylotarg ) was the first antibody-drug conjugate to be approved - for CD33-positive acute myeloid leukemia (AML). However, it was voluntarily withdrawn from the US market due to...

Pharmacokinetic-pharmacodynamic modeling of cyadox against Escherichia coli in swine.

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.

This study determined individual optimal amrubicin doses for Japanese patients with lung cancer after platinum-based treatment. We conducted population pharmacokinetic and pharmacodynamic modeling inc...

Clinical Trials [7328 Associated Clinical Trials listed on BioPortfolio]

Pharmacodynamic Interaction of REMI and DMED

The objective is to map the pharmacokinetic / pharmacodynamic interaction between dexmedetomidine and remifentanil by observing changes in anesthetic depth. These changes will be related t...

Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)

In this prospective observational study, the investigators want to document pharmacokinetic/pharmacodynamic (PK/PD) target attainment of frequently used antimicrobials in an adult non crit...

Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain

The primary objective of this study is to develop a pharmacokinetic (PK) and a pharmacokinetic-pharmacodynamic (PK-PD) model for gabapentin in patients with neuropathic pain. The se...

Model for PK/PD of Antimicrobials in Blood Stream Infection: Feasibility

The current study is a pilot study to assess the feasibility of a superordinate project. The final objective of this superordinate project is to describe and model the pharmacokinetic beha...

Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

The study was an assessor-blind, balanced, randomized, two-treatment, two-period, single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD) study of subcut...

Medical and Biotech [MESH] Definitions

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Measurement of cells' substrate utilization and biosynthetic output for modeling of METABOLIC NETWORKS.

QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position.

A statistical tool for detecting and modeling gene-gene interactions. It is a non-parametric and model-free approach.

Transfer from pediatric to adult care.

Quick Search


DeepDyve research library

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...


Searches Linking to this Article